- Home
- APLT vs CAAS Comparison
APLT vs CAAS Comparison
Compare APLT & CAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- CAAS
- Stock Information
- Founded
- APLT 2016
- CAAS N/A
- Country
- APLT United States
- CAAS China
- Employees
- APLT N/A
- CAAS N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- CAAS Auto Parts:O.E.M.
- Sector
- APLT Health Care
- CAAS Consumer Discretionary
- Exchange
- APLT Nasdaq
- CAAS Nasdaq
- Market Cap
- APLT 178.6M
- CAAS 148.1M
- IPO Year
- APLT 2019
- CAAS N/A
- Fundamental
- Price
- APLT $1.30
- CAAS $4.37
- Analyst Decision
- APLT Buy
- CAAS
- Analyst Count
- APLT 5
- CAAS 0
- Target Price
- APLT $4.13
- CAAS N/A
- AVG Volume (30 Days)
- APLT 5.5M
- CAAS 34.6K
- Earning Date
- APLT 11-10-2025
- CAAS 11-12-2025
- Dividend Yield
- APLT N/A
- CAAS N/A
- EPS Growth
- APLT N/A
- CAAS N/A
- EPS
- APLT N/A
- CAAS 0.97
- Revenue
- APLT $121,000.00
- CAAS $696,272,000.00
- Revenue This Year
- APLT N/A
- CAAS N/A
- Revenue Next Year
- APLT $5,935.35
- CAAS N/A
- P/E Ratio
- APLT N/A
- CAAS $4.51
- Revenue Growth
- APLT N/A
- CAAS 17.08
- 52 Week Low
- APLT $0.30
- CAAS $3.50
- 52 Week High
- APLT $10.62
- CAAS $5.37
- Technical
- Relative Strength Index (RSI)
- APLT 62.38
- CAAS 46.01
- Support Level
- APLT $1.16
- CAAS $4.27
- Resistance Level
- APLT $1.50
- CAAS $4.55
- Average True Range (ATR)
- APLT 0.15
- CAAS 0.16
- MACD
- APLT -0.01
- CAAS -0.00
- Stochastic Oscillator
- APLT 66.64
- CAAS 44.82
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About CAAS China Automotive Systems Inc.
China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.